Genmab — Juli 2022
-
-
TIVDAK launch progressing well
• Pleased with positive feedback from oncology community
• Well-positioned in 2L/3L setting; area of high unmet need
https://s21.q4cdn.com/327105422/files/doc_financials/2022/q2/revised/SGEN-2Q22-Presentation-28July2022.pdf -
That will be all net sales and no collaboration rev. Wonder when Genmab will book first sale?
-
Could be. I may ask Mr. Winkel at our next QA. The sales force at Genmab is hopefully busy practicing for Epco release. But would be nice to see some numbers to prove they are progressive now and not just pulling their monthly payment
-
I assumed Genmab would co-op in US
-
-
Aktier/åbning: Vestas igen med fremme i grøn start for C25
https://www.proinvestor.com/investornyt/857841/aktier-abning-vestas-igen-med-fremme-i-gron-start-for-c25 -
Genmab is co-promoting Tivdak in the U.S. and will lead
commercial operational activities in Japan. Seagen is leading commercial operational activities in the
U.S. and will lead commercial operational activities in Europe and China. In these four markets there will
be a 50:50 cost and profit split. In any other markets, Seagen will commercialize Tivdak and Genmab will
receive royalties based on a percentage of aggregate net sales ranging from the mid-teens to the midtwenties. T -
Fra aftalen 2017 "Each party has the option to co-promote by employing up to 40 percent of the sales effort in the other party's territories."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind